Forus raises $150M at $3B valuation for AI drug access platform

Sep 8, 2026

Healthcare automation startup Forus raised $150 million in Series C funding led by Bain Capital Ventures, tripling its valuation to $3 billion in four months. The New York-based company uses AI agents to streamline the complex, multi-step administrative process between a doctor's prescription and a patient starting treatment. Currently operating in all 50 states and partnering with nine of the 15 largest biopharma firms, Forus plans to use the capital to expand into new medical specialties and scale its technology.

Forus Series C funding round

▪The Series C funding round was led by Bain Capital Ventures, with participation from Thrive Capital, General Catalyst, Accel, Redpoint, BoxGroup, Pear VC, Avra, Human Capital, Neo, Vast Ventures, and SV Angel
▪Forus, which was founded in 2023 and was previously known as Tandem, is a New York-based startup
▪The Series C round brings the total funding raised by Forus, which previously raised $160 million in May 2026, to more than $300 million
▪Healthcare automation startup Forus announced on September 8, 2026, that it raised $150 million in a Series C funding round
▪The Series C funding round valued Forus at $3 billion, tripling its valuation in approximately four months

AI-powered drug access platform

▪The Forus platform is free for healthcare providers and patients, utilizing data from millions of cases to accelerate the drug access process
▪The Forus platform uses AI agents to connect doctors, pharmacies, payers, and biopharma to automate administrative tasks between a provider prescribing a medication and a patient starting treatment

Prescription-to-treatment workflow challenges

▪According to Forus CEO Sahir Jaggi, one-third of patients prescribed medications for high-cost or complex conditions never receive their first dose
▪According to Forus CEO Sahir Jaggi, a single prescription can require up to 15 steps across insurance approvals, financial assistance, specialty pharmacy routing, and fulfillment

Platform expansion investment priorities

▪Forus aims to expand its platform to every doctor's office across the United States to make the development, launch, and delivery of medicines faster and more predictable
▪Forus plans to use the Series C proceeds to deepen its platform with more AI agents and clinical models, expand to all medical specialties and sites of care, and grow its technical and go-to-market teams

Biopharma company partnerships

▪Forus partners and works with nine of the world's fifteen largest biopharmaceutical companies
▪Bain Capital Ventures general partner Kevin Zhang stated that the largest companies in medicine have turned to Forus to bring their newest medicines to patients

Healthcare provider adoption nationwide

▪The Forus platform is used by healthcare providers across all 50 U.S. states
▪The Forus platform serves patients residing in 85% of residential ZIP codes in the United States

Debatable claims

▪AI should not automate patient insurance approvals for prescribed medications
▪Biopharmaceutical companies should not partner with AI platforms that manage drug access